| Document |
Document Title |
|
WO/2013/060889A1 |
The invention relates to oseltamivir derivatives as influenza neuraminidase inhibitors for treating influenza infections and to a method for producing said compounds.
|
|
WO/2013/056559A1 |
Provided are a modified diphenylmethane diisocyanate (MDI) biuret curing agent and preparation method thereof, the curing agent being prepared by reacting dibasic alcohol, water and MDI in an organic solvent; the molar ratio between the ...
|
|
WO/2013/030358A1 |
The invention relates to 4-aminonaphthalene-2-carboxylic acids and 1-amino- isoquinoline-3-carboxylic acids as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compou...
|
|
WO/2013/017714A1 |
The present invention relates to a family of new compounds of general formula (I) that act as low-molecular-weight organogels for a wide variety of solvents and that provide a gel that is very stable at high temperatures. General formula...
|
|
WO/2012/165398A1 |
The present invention relates to a compound having an excellent DGAT inhibitory activity and an anti-feeding activity or a pharmacologically acceptable salt thereof. A compound represented by general formula (I) [wherein R represents a p...
|
|
WO/2012/159557A1 |
The present invention relates to a substituted triazine phenylurea derivative and a use thereof as an inhibitor of protein kinases, especially Raf-1, and the compound of the present invention is useful in treatment of various disorders a...
|
|
WO/2012/138706A1 |
Compounds and compositions comprising epoxyeicosatrienoic acid (EET) analogs that act as EET agonists and are useful as medications in the treatment of drug-induced nephrotoxicity, hypertension and other related conditions. Methods of ma...
|
|
WO/2012/134943A1 |
Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, or combinations thereof, (I) wherein X1, X2, X3, X4, J, K, L, X5, X6, Rb, G2, and m are defined in the specification. Compositions comprising s...
|
|
WO/2012/121394A1 |
The present invention provides a substituted aromatic compound represented by general formula (I) [wherein A1, A2 and A3 independently represent an aryl group substituted by a hydrophilic group].
|
|
WO/2012/117099A1 |
The present invention relates to a process for preparing polyisocyanates containing biuret groups from di- or polyisocyanates with diamines.
|
|
WO/2012/108478A1 |
The present invention is a compound represented by formula (I) (in the formula, each of the reference numerals is as recited in the specification) or a salt thereof.
|
|
WO/2012/100532A1 |
A modified 1,6-hexamethylene diisocyanate biuret curing agent and a preparation method therefor. The 1,6-hexamethylene diisocyanate biuret curing agent is formed by reacting a diol, water, and 1,6-hexamethylene diisocyanate in an organic...
|
|
WO/2012/089137A1 |
Disclosed in the present invention is an arylurea compound represented by formula I, or a pharmaceutically acceptable salt, a polymorph, a solvate or a stereoisomer thereof, and an intermediate and use thereof. The arylurea compound I of...
|
|
WO/2012/088776A1 |
Preparation methods of 2-(N-substituted)-amino-benzimidazole derivatives are disclosed, compring such steps: (1) reacting 2-(N-protecting group)-benzene-1,2-diamines with N- phenoxycarbonylamines to obtain 2-(N-substituted)-amino-aryl ur...
|
|
WO/2012/081885A2 |
The present invention relates to compounds 1, 1a (S-enantiomer) and 1b (R-enantiomer) of the following formula 1, and a method for preparing the same. [formula 1] The novel compound of the formula 1 is used as an important intermediate f...
|
|
WO/2012/069605A1 |
The present invention relates to a novel class of E,E-diene compounds and their use as a medicament, preferably as a dermatologic agent, and as a cosmetic. These novel compounds are particularly useful in treating and/or preventing infla...
|
|
WO/2012/064417A1 |
The present invention comprises a compound of a compound of Formula 1 wherein Rf is a C2 to C-12 perfluoroalkyl optionally interrupted by one to four moieties each independently selected from the group consisting of -CH2-, -O-, -S-, -S(O...
|
|
WO/2012/056014A1 |
Compounds of the formula (I) or salts thereof, wherein R1 represents alkyl, aryl, alkyl-aryl or aryl-alkyl, compositions containing same, and their use in counteracting human axillary malodour.
|
|
WO/2012/054996A1 |
The present invention relates to functionalized aryl and/or heteroaryl urea compounds of general formula (I) and (II), and also salts and/or solvates and polymorphs thereof which can inhibit protein kinases from the MAPK family and also ...
|
|
WO/2012/050041A1 |
The present invention provides a pest control agent, an acaricide, or a bactericide that contains, as the active ingredient thereof, at least one type of compound selected from aryloxyurea compounds represented by formula (V) (wherein R1...
|
|
WO/2012/050482A1 |
Carbamide is produced at a high temperature and pressure in a plant which comprises a high pressure section including a reactor, a stripper, a condenser and a scrubber. Ammonia and carbon dioxide are reacted in the reactor to form a reac...
|
|
WO/2012/028676A1 |
The invention relates to new compounds of the formula (I) to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
|
|
WO/2012/004549A1 |
A compound of formula I-0, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: wherein Z1 is C1-C4 linear or branched alkyl or alkenyl; R4 is selected from unsubstitut...
|
|
WO/2011/157612A2 |
The invention relates to novel compounds derived from amino acids of formula (I) and also to cosmetic or dermatological compositions containing them and to their use as agents for treating human perspiration in a cosmetic composition. Th...
|
|
WO/2011/159137A2 |
The present invention relates to a novel thiourea or urea derivative, a preparation method thereof, and a pharmaceutical composition for preventing or treating AIDS, containing the same as an active ingredient. According to the present i...
|
|
WO/2011/157611A2 |
The invention relates to novel compounds derived from amino acids of formula (I) and also to cosmetic or dermatological compositions containing them and to their use as agents for treating human perspiration in a cosmetic composition. Th...
|
|
WO/2011/140680A1 |
The present invention discloses compounds of formula (I), isomers, pharmaceutical salts or solvates thereof. The present invention also discloses a composition comprising the compounds of formula (I), isomers, pharmaceutical salts or sol...
|
|
WO/2011/140832A1 |
The present invention discloses a compound of general formula (I), or isomer, pharmaceutically acceptable salt and solvate thereof, as well as composition, medicinal use, and preparative method thereof. Said composition further comprises...
|
|
WO/2011/136231A1 |
Disclosed is a process for producing a high-purity bisaminophenylalkylurea as the desired compound in high yield while attaining a high volumetric efficiency and generating little by-product. A (nitrophenyl)alkylamine hydrohalogenide rep...
|
|
WO/2011/131576A1 |
Tranylcypromine derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of histone demethylases LSD1 and LSD2, such as the diseases characterized ...
|
|
WO/2011/122917A2 |
The present invention relates to an octahydrobinaphthol derivative which recognizes an amino acid and amino alcohol in a chiral-selective manner, converts L-amino acid into D-amino acid, and performs optical resolution on an amino acid a...
|
|
WO/2011/113368A1 |
A fluoro-substituted deuterated diphenylurea compound, especially 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluoro
phenoxy)- 2-(N-1',1',1'-d3-methyl)picolinamide, preparing method and use for treating or preventing tumor and ...
|
|
WO/2011/113367A1 |
Methods and processes for preparation and production of deuterated ω-diphenylure are disclosed. Especially, a kind of deuterated ω-diphenylurea compounds which can inhibit phosphokinase and the preparation method of N-(4-chloro-3-(trif...
|
|
WO/2011/108690A1 |
The disclosed composition containing a compound represented by general formula (I) (refer to the Description for the definitions of the symbols used in the formula), or a salt thereof, has excellent CaSR agonist effects and provides phar...
|
|
WO/2011/108724A1 |
An object is to provide a CaSR agonist agent that has excellent CaSR agonist effects, and particularly, a pharmaceutical product that can prevent or remedy diabetes or obesity by the effect of CaSR activation. The aforementioned object i...
|
|
WO/2011/084106A1 |
Disclosed herein is a compound of structure (A): In this compound, X is either O or S, R1 is a rigid group, R2 is a hydrophilic group such that (A) is capable of self-assembly in water, and R3 is an organic group.
|
|
WO/2011/076784A2 |
The present invention relates to a compound of formula (I): Formula (I), wherein: - n is 0, 1 or 2; - A is in particular CH or N; - X is in particular CO, SO2, CS, and R1 is in particular H, - R2 is a group of formula NR3R4 or OR5, R3 an...
|
|
WO/2011/071078A1 |
Provided is an oligonucleotide derivative, the 3′ end of which is chemically modified with two skeletons selected from among benzene skeletons and pyridine skeletons. Said oligonucleotide derivative can be easily synthesized in a small...
|
|
WO/2011/066414A1 |
The present invention provides arachidonic acid (AA) analogs and compositions containing those analogs as active agents for use in analgesic treatments. Various methods of r manufacturing the inventive compounds are provided and pharmace...
|
|
WO/2011/039735A2 |
The present invention relates to the medical use of the compound of formula 1, 2, 3 or 4:
|
|
WO/2011/040509A1 |
In order to provide a low molecular weight compound that has p38MAPK inhibitory activity and the accompanying TNFα production suppression activity and that has a favorable pharmacokinetic profile as a pharmaceutical and decreased hepato...
|
|
WO/2011/034078A1 |
Disclosed is a compound which is useful as the active ingredient of a medicinal composition, in particular, a medicinal composition for preventing and/or treating a VAP-1 associated disease. As the results of intensive studies on compoun...
|
|
WO/2011/022489A2 |
The invention provides for novel (bis)urea and (bis)thiourea compounds which are inhibitors of lysine- specific demethylase 1 (LSD1). Such compounds may be used to treat disorders, including cancer.
|
|
WO/2011/019928A1 |
A modular system and method for producing urea from stranded natural gas includes removal of foreign particulate matter to obtain a substantially homogeneous gas. The gas is processed by controlling the quality of the stranded natural ga...
|
|
WO/2011/017201A2 |
Described herein is the DP2 antagonist [2'-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4'-trifluorome
thyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonis...
|
|
WO/2011/001122A2 |
The invention relates to pyrazole derivatives of the general formula (I), where X is chlorine or fluorine. The invention also relates to a method for preparing same and to the therapeutic use thereof.
|
|
WO/2010/150255A1 |
Novel compounds and pharmaceutical compositions are provided. In one aspect of the invention the compounds may be utilized in medical practice, for example, in treatment of cancer and immune disorders. In another aspect of the invention ...
|
|
WO/2010/143409A1 |
Disclosed are: a process for producing a salt of an optically active thiazolylalanine derivative which has a desired configuration by converting a thiazolylalanine derivative into a salt thereof and crystallizing a compound having one of...
|
|
WO/2010/144055A1 |
The invention relates to compounds represented by the general formula (I): and pharmaceutically acceptable salts thereof, wherein n is an integer from 1 to 5; p is an integer from 0 to 4; R1 is selected from the group consisting of a hyd...
|
|
WO/2010/112946A9 |
The invention relates to adamantane bisurea derivatives and their use. Adamantane bisurea derivatives are obtained by reaction of adamantane diamine with appropriate isocyanate, or by in situ preparation of adamantane isocyanate from ada...
|
